The Final Stages of Myelodysplastic Syndromes (MDS): What to Expect

Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a healthcare professional for guidance specific to your or your loved one’s condition.

Understanding Myelodysplastic Syndromes (MDS)

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders where the bone marrow fails to produce enough healthy, mature blood cells. Often called a "bone marrow failure disorder," MDS is characterized by ineffective hematopoiesis, a process where blood cells are produced defectively and undergo premature apoptosis (cell death) before they can enter the bloodstream. According to the National Cancer Institute (NCI), MDS affects approximately 3 to 5 people per 100,000 annually, with incidence rising sharply in adults over age 60. MDS leads to a shortage of one or more types of blood cells:

• Red Blood Cells (Anemia): Causes fatigue, weakness, shortness of breath, and pale skin. Chronic anemia forces the cardiovascular system to compensate, often leading to tachycardia and reduced exercise tolerance.
• White Blood Cells (Neutropenia): Weakens the immune system, leading to frequent and severe infections. Patients may experience recurrent bacterial or fungal infections that require prolonged antibiotic or antifungal therapies.
• Platelets (Thrombocytopenia): Impairs blood clotting, causing easy bruising, bleeding, and tiny red spots on the skin (petechiae). Severe thrombocytopenia increases the risk of mucosal bleeding (e.g., gums, nose) and internal hemorrhage.

MDS most commonly affects older adults, with the average age of diagnosis around 70. While some forms progress slowly, higher-risk MDS can be aggressive and may transform into acute myeloid leukemia (AML). The condition can be classified as primary (arising spontaneously due to age-related genetic mutations in hematopoietic stem cells) or secondary (therapy-related, developing as a late complication of prior chemotherapy or radiation therapy for another malignancy). Secondary MDS often carries a poorer prognosis and higher genetic complexity, as documented by the World Health Organization (WHO) classification systems for hematopoietic tumors. Discussing the final stages of MDS is difficult, but understanding the process can help patients, families, and caregivers prepare and focus on providing comfort and support.

How MDS Progresses: Risk Categories, Not Stages

Unlike solid tumors classified by anatomical stages (I-IV), MDS is categorized using prognostic scoring systems that evaluate disease biology and clinical severity. The most common historical system is the Revised International Prognostic Scoring System (IPSS-R), which groups MDS into five risk categories from "Very Low" to "Very High." More recently, the Molecular International Prognostic Scoring System (IPSS-M) has been integrated to incorporate next-generation sequencing data, providing a more precise prediction of survival and leukemic transformation. This scoring approach helps predict the disease's course and is based on:

• The percentage of immature "blast" cells in the bone marrow. Blasts normally represent less than 5% of nucleated marrow cells. A blast percentage exceeding 5% indicates higher disease activity, while reaching 20% or more classifies the condition as overt AML.
• The severity of low blood counts (cytopenias). Persistent and profound drops in hemoglobin, platelets, and absolute neutrophil count directly correlate with symptom burden and complication risk.
• Specific genetic abnormalities in the bone marrow cells. Cytogenetic analysis identifies chromosomal deletions (e.g., del5q, del20q, -7) and somatic mutations (e.g., TP53, ASXL1, RUNX1, TET2) that drive disease progression and dictate treatment responsiveness.

Lower-risk MDS often progresses slowly, allowing for many years of life with supportive care. Management may include erythropoiesis-stimulating agents (ESAs) for anemia, iron chelation therapy to manage transfusion-induced iron overload, and targeted therapies like luspatercept for patients with ring sideroblasts. Higher-risk MDS can advance more quickly, with a greater chance of transforming into AML. Treatment, including medications like hypomethylating agents (azacitidine, decitabine) or intensive chemotherapy followed by an allogeneic stem cell transplant (the only potential cure), can significantly alter this course. As highlighted by Mayo Clinic experts, transplant eligibility depends heavily on age, comorbidities, and performance status. Good Morning America anchor Robin Roberts, who received a bone marrow transplant for MDS, is a well-known example of a successful outcome. However, for those who cannot receive a transplant or whose disease no longer responds to treatment, MDS can become terminal.

Complications Leading to End-of-Life in MDS

As MDS advances, the failing bone marrow leads to severe, life-threatening complications that are often the direct cause of death. Understanding these physiological pathways helps healthcare teams anticipate crises and implement proactive comfort measures.

• Severe Anemia and Cardiac Strain: Extreme fatigue and shortness of breath can strain the heart, leading to high-output heart failure. When hemoglobin drops below critical thresholds (often <7-8 g/dL), the heart compensates by increasing cardiac output, which over time weakens myocardial function. Frequent blood transfusions may cause iron overload (secondary hemochromatosis), depositing iron in the liver, heart, and endocrine organs, causing cirrhosis, arrhythmias, or diabetes if not carefully managed with chelation therapy.
• Life-Threatening Infections and Sepsis: A lack of healthy white blood cells (particularly neutrophils) makes the body profoundly vulnerable to opportunistic pathogens. A minor cut, dental procedure, or common respiratory virus can quickly escalate into pneumonia, fungal bloodstream infections, or sepsis. The CDC notes that neutropenic patients require strict monitoring for fever (often the only early sign of infection), as the classic signs of inflammation are blunted. Sepsis-induced hypotension and multiorgan failure remain leading causes of death in advanced MDS.
• Uncontrolled Bleeding (Hemorrhage): Critically low platelet counts (<10,000-20,000/μL) impair primary hemostasis, leading to spontaneous and severe bleeding. This manifests as persistent epistaxis, heavy gastrointestinal bleeding, or life-threatening intracranial hemorrhage. Repeated platelet transfusions can lead to alloimmunization, where the immune system develops antibodies against donor platelets, rendering future transfusions ineffective (platelet refractoriness).
• Progression to Acute Myeloid Leukemia (AML): About 20-30% of MDS cases, particularly high-risk ones, transform into secondary AML. This shift causes a rapid clinical decline as malignant blasts crowd out remaining healthy marrow and infiltrate other organs (extramedullary disease), leading to liver/spleen enlargement, gum hypertrophy, and neurological symptoms. Organ failure, overwhelming infection, or catastrophic bleeding during this transition are common.

"You matter because you are you, and you matter to the last moment of your life. We will do all we can, not only to help you die peacefully, but also to live until you die."
– Dame Cicely Saunders, founder of the modern hospice movement.

The Journey Through the Final Stages of MDS

While not a formal medical classification, the end-of-life process for MDS can be understood through general phases of decline. Every individual's journey is unique, influenced by age, baseline comorbidities, treatment history, and personal physiology. Recognizing these transitions allows families to adjust care goals and environments appropriately.

Early Phase (Months Before)

• Increasing Fatigue: The person tires more easily and needs more rest. Anemia worsens despite transfusions, and mitochondrial dysfunction contributes to persistent energy depletion. Patients often begin pacing activities and conserving strength for essential tasks.
• Higher Transfusion Needs: Blood or platelet transfusions are required more frequently (e.g., moving from monthly to weekly visits), and their benefits may not last as long due to shortened red cell survival and splenomegaly. Iron levels should be monitored closely.
• Symptom Management: Discussions about palliative care may begin to focus on managing symptoms and improving quality of life. This phase is ideal for completing advance directives, designating healthcare proxies, and discussing resuscitation preferences (DNR/DNI orders) while the patient can actively participate.

Mid Phase (Weeks to Months Before)

• Frequent Hospitalizations: Stays for infections or transfusions become more common. The burden of travel and clinical interventions begins to outweigh the benefits, prompting many to shift toward home-based care with visiting nursing services.
• Physical Decline: Noticeable weight loss, muscle wasting (cachexia), and a poor appetite may occur. The body's metabolic demands shift, and inflammatory cytokines suppress hunger signals. Swallowing difficulties or dry mouth from medications may further reduce oral intake.
• Increased Need for Support: Help with daily activities like personal care, cooking, and mobility becomes necessary. Fall risk increases significantly due to weakness and orthostatic hypotension. Home modifications (grab bars, shower chairs, hospital beds) and medical equipment (wheelchairs, oxygen concentrators) become essential.

Advanced Phase (Weeks to Days Before)

• Severe Weakness: The person spends most of their time in bed or resting. Even sitting upright may require significant assistance. Caregivers should focus on skin integrity, using specialized mattresses and repositioning schedules every two hours to prevent pressure ulcers.
• Worsening Symptoms: Shortness of breath may occur even at rest due to severe anemia and potential pulmonary edema. Bruising and bleeding can happen with little provocation, requiring gentle handling and meticulous oral care with soft swabs.
• Pain and Discomfort: While MDS itself isn't always painful, complications like severe infections, bone marrow expansion, or joint bleeding may require pain management. Sublingual, transdermal, or continuous subcutaneous infusions of medications are often preferred when swallowing becomes unreliable.
• Emotional Withdrawal: The person may become less communicative and more withdrawn as they begin to detach emotionally and spiritually. This "social dying" is a natural, often protective response to overwhelming fatigue. Family members are encouraged to sit quietly, share memories, and avoid forcing interaction.

Final/Active Dying Phase (Days to Hours Before)

In the last days, the body begins its final, natural process of shutting down. Physiological changes become more pronounced, and the focus shifts entirely to comfort.

• Profound Weakness: The person is often unresponsive or drifts in and out of consciousness. Sleep-wake cycles disappear. Eyes may remain partially open, and facial muscles may relax significantly.
• Loss of Appetite: There is little to no interest in food or drink. This is a normal part of the process, not starvation. Forcing food or fluids can cause choking, nausea, or pulmonary aspiration. Artificial hydration is generally discouraged as it can worsen respiratory secretions.
• Changes in Breathing: Breathing may become shallow, irregular, or produce a rattling sound (a "death rattle") due to the relaxation of throat muscles and pooling of saliva in the oropharynx. Repositioning the head and using anticholinergic medications (like scopolamine or glycopyrrolate) can reduce distressing sounds.
• Circulation Changes: Hands and feet may feel cool to the touch and appear bluish or mottled (livedo reticularis) as peripheral vasoconstriction redirects blood to vital organs. Capillary refill time slows significantly.
• Decreased Consciousness: The person may sleep most of the time. However, hearing is one of the last senses to fade, so speaking softly, playing calming music, and holding their hand can be a great source of comfort.

The Role of Palliative Care and Hospice

Palliative care can be introduced at any stage of a serious illness to manage symptoms and improve quality of life. It is not just for the end of life, but rather a parallel support system that works alongside disease-directed therapies. According to the Cleveland Clinic, palliative specialists address physical symptoms (pain, fatigue, nausea, dyspnea), psychological distress (anxiety, depression), and existential concerns (meaning, spiritual distress, advance care planning). For MDS patients, it focuses on relieving debilitating symptoms while supporting emotional and spiritual needs, ensuring that treatment decisions align with the patient's values and goals.

Hospice care is a specific type of palliative care for individuals with a life expectancy of six months or less, should the disease follow its natural course. When curative or life-prolonging treatments for MDS are no longer working, causing unacceptable toxicity, or are no longer desired, hospice shifts the focus entirely to comfort and dignity. A hospice team provides expert medical care, emotional support, and spiritual guidance, usually in the patient's home, but also in hospice facilities, assisted living, or hospitals. Coverage typically includes all necessary medications, medical equipment, nursing visits, and bereavement counseling for family members for up to 13 months after the death.

Accepting hospice care is not "giving up"; it is a choice to prioritize quality of life, ensuring a person’s final days are as peaceful and meaningful as possible. Hospice empowers families by providing 24/7 clinical support, respite care, and guidance through the dying process, reducing emergency department visits and unwanted hospitalizations during the most fragile period.

Coping with the Emotional Journey

Patients and their families often experience a range of powerful emotions, sometimes described by the Kübler-Ross model: denial, anger, bargaining, depression, and acceptance. These stages are not linear, and people may move between them rapidly or experience multiple simultaneously. Grief begins at diagnosis (anticipatory grief), and caregivers frequently report feeling overwhelmed by the unpredictable nature of MDS complications, the emotional toll of repeated hospitalizations, and the weight of complex medical decisions.

Supporting Emotional Health:

• Open Communication: Create a safe space to talk about fears, wishes, and feelings. Use "I" statements and validate emotions without offering unsolicited solutions. Regular family meetings facilitated by a social worker or chaplain can align care expectations.
• Support Groups: Connecting with others who understand the journey can reduce feelings of isolation. Organizations like the Leukemia & Lymphoma Society (LLS) and the Aplastic Anemia and MDS International Foundation (AAMDSIF) offer valuable resources, virtual communities, and peer mentorship programs specifically for blood cancer patients and families.
• Professional Counseling: Therapists specializing in psycho-oncology, chronic illness, or grief can provide evidence-based coping strategies (such as CBT or mindfulness-based stress reduction) for both patients and caregivers. Addressing caregiver burnout early is crucial, as exhaustion impairs decision-making and physical caregiving ability.
• Create a Legacy: Some find comfort in writing letters, creating memory books, recording video messages, or sharing important life stories. Rituals like life review sessions, spiritual ceremonies, or planting a memorial garden can provide profound meaning and closure.

You can find helpful webinars and videos on coping with blood cancers on the Leukemia & Lymphoma Society website or its official YouTube channel. Additionally, exploring literature on narrative medicine or participating in art and music therapy programs offered by cancer centers can facilitate emotional expression when words feel inadequate.

Helpful Resources & Further Reading

For more detailed information and support, consult these reputable organizations and authoritative medical resources:

• American Cancer Society: Provides a comprehensive guide to Myelodysplastic Syndromes, from diagnosis to treatment and coping. https://www.cancer.org/
• Leukemia & Lymphoma Society (LLS): Offers patient-friendly information, financial aid, and support services for those affected by MDS. https://www.lls.org/
• Aplastic Anemia and MDS International Foundation (AAMDSIF): A dedicated resource for bone marrow failure diseases, providing education, support networks, and research updates. https://www.aamds.org/
• The MDS Foundation: Focuses on patient support, education for medical professionals, and MDS research. https://www.mds-foundation.org/
• National Institute on Aging: Offers excellent guides on end-of-life care, palliative care, and hospice that are helpful for any terminal illness. https://www.nia.nih.gov/
• Mayo Clinic: Detailed medical overviews on MDS symptoms, diagnosis, prognosis, and end-of-life care planning. https://www.mayoclinic.org/
• National Institutes of Health (NIH): Access clinical trial databases, research updates, and patient education materials on myelodysplastic disorders. https://www.nih.gov/
• CDC Infection Prevention Resources: Guidelines for protecting immunocompromised individuals from severe infections. https://www.cdc.gov/

Frequently Asked Questions

What is the average life expectancy for high-risk MDS without treatment?

Life expectancy for untreated high-risk MDS varies widely based on age, performance status, and specific genetic mutations, but it is generally measured in months to a few years. Without disease-modifying therapy like a stem cell transplant or hypomethylating agents, patients with higher-risk scores (e.g., IPSS-R High or Very High) typically have a median survival of less than 1.5 to 2 years, largely due to complications from infections, bleeding, or transformation to acute myeloid leukemia. However, individual trajectories depend heavily on overall health and supportive care quality.

Can MDS be misdiagnosed as another condition?

Yes, MDS is frequently misdiagnosed or delayed in diagnosis, particularly in older adults. Its symptoms—chronic fatigue, frequent infections, and easy bruising—closely mimic common age-related conditions like nutritional deficiencies (B12, folate), autoimmune disorders, viral infections, or other bone marrow failure syndromes like aplastic anemia. Definitive diagnosis requires a bone marrow aspiration and biopsy with specialized cytogenetic and molecular testing to identify dysplastic changes, blast percentage, and clonal genetic mutations.

What are the signs that hospice care is needed for an MDS patient?

Hospice is generally appropriate when disease-directed treatments are no longer effective, the patient has a poor performance status (ECOG 3 or 4, meaning they spend more than 50% of waking hours in bed or a chair), and life expectancy is estimated at six months or less. Specific clinical indicators include: frequent hospitalizations despite optimal supportive care, transfusion dependence that no longer stabilizes symptoms, recurrent severe infections or bleeding, significant unintentional weight loss (>10% body weight in 6 months), and the patient's clear preference to prioritize comfort over aggressive interventions.

How does a stem cell transplant affect the end-of-life trajectory for MDS?

An allogeneic stem cell transplant is the only potentially curative option for MDS but carries significant risks. For patients who successfully undergo engraftment, the trajectory can shift toward long-term remission or cure, fundamentally altering the end-of-life expectation. However, transplant-related mortality remains a concern, particularly in older patients or those with extensive comorbidities. Complications like severe graft-versus-host disease (GVHD), opportunistic infections, or organ toxicity can lead to decline. If transplant fails or relapse occurs, the disease typically follows an accelerated course, necessitating a swift transition to palliative and hospice care.

What is the difference between palliative care and hospice for MDS patients?

Palliative care and hospice share the same goal of symptom relief and quality-of-life improvement, but they differ in timing and treatment approach. Palliative care can be integrated at any point after diagnosis, even while a patient is still receiving chemotherapy, hypomethylating agents, or pursuing a transplant. It focuses on managing side effects, clarifying goals of care, and supporting mental health. Hospice is a subset of palliative care specifically for patients who have discontinued curative or life-prolonging treatments and have a prognosis of six months or less. Hospice provides a comprehensive, Medicare-certified package of home-based care, equipment, medications, and bereavement support, with the explicit goal of comfort rather than disease modification.

Conclusion

Myelodysplastic syndromes represent a complex spectrum of bone marrow disorders that progress through biological risk categories rather than traditional cancer stages. While lower-risk forms may remain manageable for years with supportive therapies, higher-risk MDS can lead to severe cytopenias, recurrent complications, and eventual transformation to acute myeloid leukemia. Understanding the natural progression of the disease, recognizing the signs of clinical decline, and preparing for potential complications empowers patients and families to navigate this challenging journey with greater clarity and dignity.

As the disease advances, the focus of care must thoughtfully transition from life-prolonging interventions to comfort-centered management. Palliative care and hospice services play indispensable roles in alleviating physical symptoms, providing psychological and spiritual support, and guiding families through the emotional complexities of end-of-life decision making. Recognizing the signs of active dying, prioritizing symptom relief over routine medical procedures, and fostering open, compassionate communication can transform the final chapter into one of peace, connection, and meaningful closure. With the support of specialized healthcare teams, reputable organizations, and dedicated caregivers, individuals living with MDS can experience the highest possible quality of life, right to the very end.